ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "systemic lupus erythematosus (SLE)"

High-Salt Diet May Trigger Gene Silencing & a Lupus Phenotype

Lara C. Pullen, PhD  |  August 15, 2016

New research has demonstrated that a high-salt diet may increase the differentiation of follicular helper T cells (Tfh). A high-salt diet also increased lupus features in MRL/lpr mice, suggesting that the genes that increased expression in response to salt intake were similar to the genes that had increased expression in lupus CD4+ T cells…

Plasmabast Responses Provide a Signature for Lupus Disease Activity

Lara C. Pullen, PhD  |  August 8, 2016

A recent study documented blood transcriptional profiles in pediatric patients with systemic lupus erythematosus (SLE), finding that plasmablast signatures were the most robust biomarker of SLE disease activity. Researchers were further able to stratify patients into groups on the basis of molecular correlates, which may aid in personalizing SLE treatment and identifying biomarkers that can predict occurrence and frequency of flares…

Researchers Hone in on Defect in Autophagy that May Underlie Lupus

Lara C. Pullen, PhD  |  June 13, 2016

New research investigates the role of autophagy, specifically the cell digestion process called LC3-associated phagocytosis (LAP), in inflammation and the pathology of systemic lupus erythematosus (SLE). Researchers found that defects in this process result in failure to digest dying cells, which increases inflammatory cytokine production and results in SLE-like disease in mice. Further exposure to dying cells accelerated disease development…

Researchers Calculate Comorbidity Burden for Patients with SLE

Arthritis Care & Research  |  June 7, 2016

A recent study from the U.K. calculated the incidence of comorbidity associated with systemic lupus erythematosus (SLE), specifically looking for cardiovascular disease, stroke, end-stage renal failure, cancer, osteoporosis and infection. Even after adjusting for age, sex and other variables, investigators found that people with SLE have an increased global burden of comorbidity compared with the general population. Additionally, the study found that men with SLE had higher rates of cardiovascular disease, stroke and cancer, while women with SLE had higher rates of infection and osteoporosis. Overall, younger people with SLE had the greatest relative risk compared with controls…

Bacterial Curli Amyloid: Researchers Examine the Role of Bacterial Infection in Lupus Pathology

Richard Quinn  |  June 3, 2016

New research has found that the amyloid protein curli triggers immune activation and autoantibody production in lupus-prone and wild-type mice. Stefania Gallucci, MD, says these results provide insight into the mechanisms of bacterial infection that may result in lupus…

U.K. Cost Body Finally Approves Limited Use of GSK’s Lupus Drug

Reuters Staff  |  May 12, 2016

LONDON (Reuters)—Britain’s healthcare cost watchdog has finally approved GlaxoSmithKline’s lupus drug Benlysta (belimumab) for limited use, after rejecting it since 2011 on the grounds that it failed to offer good value for money. The National Institute for Health and Care Excellence (NICE) said on Tuesday that the drug would be made available under a managed…

Patients with Lupus: Plasmacytoid Dendritic Cells Fail to Induce Regulatory B Cells

Lara C. Pullen, PhD  |  May 9, 2016

A recent study found that plasmacytoid dentricitic cells (pDCs) control the differentiation of immature B cells into regulatory B (Breg) cells or plasmablast, depending on the concentration of IFNα. For patients with SLE, researchers found that immune regulatory feedback between pDCs and Breg cells is dysfunctional, with the exception of patients who respond to rituximab…

OA Knee Pain Treatment Enters Clinical Trials, Ixekizumab Receives FDA Approval & Belimumab Promising for SLE Patients

Michele B. Kaufman, PharmD, BCGP  |  April 20, 2016

Clinical trials have begun to determine if disodium zoledronate tetrahydrate is safe and effective for treating pain in patients with knee osteoarthritis. The FDA has approved the use of ixekizumab for the treatment of plaque psoriasis. And a study has shown that patients with SLE treated with belimumab may be able to decrease steroid use…

Sifalimumab Shows Some Promise Against Lupus

Reuters Staff  |  April 15, 2016

NEW YORK (Reuters Health)—Sifalimumab, an anti-interferon alpha monoclonal antibody, may lead to some improvement in patients with systemic lupus erythematosus (SLE), according to a new trial. In a paper online on March 23 in Annals of the Rheumatic Diseases, Dr. Munther Khamashta of King’s College London and colleagues note that treatment of SLE presents a…

Vitamin D May Improve Heart Health in Patients with Lupus

Lara C. Pullen, PhD  |  April 4, 2016

A new study has found that treating patients who have systemic lupus erythematosus (SLE) with vitamin D decreases cardiovascular risk in these patients—specifically by modifying the body’s endothelial repair mechanisms. Researchers found myeloid angiogenic cells in this patient population presented with a global impairment, including decreased migration and angiogenic capacity…

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences